Higgs Biotechnology

Higgs Biotechnology is a biopharmaceutical company based in Hangzhou, China, that leverages proprietary organoid and Disease-on-a-Chip technology to revolutionize drug discovery. The company focuses on developing first-in-class small molecule therapeutics for oncology, with a particular emphasis on difficult-to-treat conditions such as diffuse gastric cancer. By utilizing patient-derived organoids, Higgs creates highly accurate disease models that better predict clinical responses compared to traditional cell lines. Their platform integrates high-throughput screening and artificial intelligence to identify novel targets and optimize drug candidates. Higgs aims to bridge the gap between preclinical research and clinical success, ultimately providing more effective treatments for cancer patients worldwide.